Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Hormones of the Pituitary Gland01:27

Hormones of the Pituitary Gland

The small, pea-sized pituitary gland is located at the base of the brain. It is crucial in regulating various bodily functions, from growth to reproduction. The gland is divided into the anterior lobe and the posterior lobe. The secretory cell clusters in the pars distalis of the anterior pituitary lobe are controlled by hypothalamic regulators and synthesize six primary hormones.
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Major Hormones and Their Functions01:27

Major Hormones and Their Functions

Hormones, the biochemical messengers produced by endocrine glands, are pivotal in regulating bodily functions and maintaining homeostasis. Each hormone's balance is crucial; imbalances can lead to significant physiological disruptions. Major hormones include oxytocin, cortisol, epinephrine, estrogen, testosterone, thyroxine, growth hormone, insulin, and glucagon.
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and lactation.
Prodrugs01:30

Prodrugs

Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Debate: Surgery as Initial Therapy for Microprolactinoma.

The Journal of clinical endocrinology and metabolism·2025
Same author

Longitudinal Trajectories of Biomarkers of Kidney Tubular Function in Type 1 Diabetes.

Kidney international reports·2024
Same author

Surveillance Imaging Strategies for Pituitary Adenomas: When, How Frequent, and When to Stop.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2023
Same author

Effects of metformin and intensive lifestyle interventions on the incidence of kidney disease in adults in the DPP/DPPOS.

Journal of diabetes and its complications·2023
Same author

Relationships Between the Cumulative Incidences of Long-term Complications in Type 1 Diabetes: The DCCT/EDIC Study.

Diabetes care·2022
Same author

Urinary Angiotensinogen in Patients With Type 1 Diabetes With Microalbuminuria: Gender Differences and Effect of Intensive Insulin Therapy.

Kidney international reports·2022
Same journal

Clinician decision-making in non-functioning pituitary adenomas: an Australian and New Zealand interdisciplinary survey study.

Pituitary·2026
Same journal

Does persistent hyperprolactinemia contribute to bone loss independently of estrogen deficiency in postmenopausal women?

Pituitary·2026
Same journal

Gauze swabbing technique for safe dissection of pituitary tumors.

Pituitary·2026
Same journal

Postoperative changes in circulating brain injury biomarkers in relation to long-term fatigue and cognitive outcomes after surgery for nonfunctioning pituitary adenomas.

Pituitary·2026
Same journal

Pituitary metastasis as an endocrine-neuro-ophthalmologic emergency: clinical red flags and outcomes from a contemporary tertiary-center series.

Pituitary·2026
Same journal

GH responsiveness to corticotropin-releasing hormone identifies corticotroph-like somatotroph adenomas in acromegaly.

Pituitary·2026
See all related articles

Related Experiment Video

Updated: Jul 6, 2026

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
12:57

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models

Published on: December 9, 2022

Drugs and prolactin.

Mark E Molitch1

  • 1Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. molitch@northwestern.edu

Pituitary
|April 12, 2008
PubMed
Summary
This summary is machine-generated.

Medications can cause elevated prolactin (hyperprolactinemia), mimicking other conditions. Differentiating drug-induced cases from other causes is crucial for proper patient management and treatment.

More Related Videos

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
13:43

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Published on: April 1, 2022

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Related Experiment Videos

Last Updated: Jul 6, 2026

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
12:57

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models

Published on: December 9, 2022

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
13:43

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Published on: April 1, 2022

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Area of Science:

  • Endocrinology
  • Pharmacology
  • Clinical Medicine

Background:

  • Medications are a frequent cause of hyperprolactinemia, necessitating differentiation from pathological conditions.
  • Antipsychotics are the most common culprits, though some atypical agents are less likely to cause this side effect.

Purpose of the Study:

  • To highlight the importance of distinguishing medication-induced hyperprolactinemia from other causes.
  • To outline diagnostic and management strategies for drug-induced hyperprolactinemia.

Main Methods:

  • Review of common medications associated with hyperprolactinemia.
  • Discussion of diagnostic approaches including medication cessation, switching medications, and neuroimaging (MRI/CT).

Main Results:

  • Medication-induced hyperprolactinemia can present with symptoms like galactorrhea, menstrual irregularities, and erectile dysfunction.
  • Diagnostic differentiation involves assessing medication history and potentially observing prolactin (PRL) level normalization after drug withdrawal or substitution.

Conclusions:

  • Accurate differentiation of medication-induced hyperprolactinemia is essential for appropriate patient care.
  • Management may involve changing medications, hormone replacement therapy, or dopamine agonist therapy.